0

538965

CONCORD

img img img img
No Data Available

Concord Drugs Limited Share Price Update

As of the latest trading session, Concord Drugs Limited is trading at ₹77, down by ₹-3.00 or -3.75% from its previous close. The stock has moved between ₹77.00 and ₹82.93 today. Over the past year, the stock has delivered a return of 143.16%. In the last month, it has returned -10.10%.

Investment Returns

Over 1 Month -10.10% Over 3 Months -3.62% Over 6 Months 3.65% Over 1 Year 143.16%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

Concord Drugs Limited fundamentals


  • Market cap (Cr) [-]
  • P/E Ratio (TTM) [-]
  • Beta [-]
  • Book Value / share [-]
  • Return on equity [-]%
  • EPS (TTM) [-]
  • Dividend yield [-]%
  • Net profit/quarter (Cr) [-]
info icon alternate text
  • Market cap (Cr) 102.40
  • P/E Ratio (TTM) 194.35
  • Beta 0.34
  • Book Value / share 34.87
  • Return on equity 0.88%
  • EPS (TTM) 0.40
  • Dividend yield [-]%
  • Net profit/quarter (Cr) 0.22
info icon alternate text

Concord Drugs Limited Financials

  • Key Results
  • Key Ratios
  • Balance sheet
  • Cash Flow
  • Competition
info-icon
Revenue
Net income
Particulars DEC 2025 (Values in Cr)
Revenue 16.84
Operating Expense 16.57
Net Profit 0.22
Net Profit Margin (%) 1.30
Earnings Per Share (EPS) 0.16
EBITDA 0.88
Effective Tax Rate (%) 27.58
Particulars SEP 2025 (Values in Cr)
Revenue 10.07
Operating Expense 9.81
Net Profit 0.19
Net Profit Margin (%) 1.88
Earnings Per Share (EPS) 0.19
EBITDA 1.01
Effective Tax Rate (%) 29.62
Particulars JUN 2025 (Values in Cr)
Revenue 13.38
Operating Expense 13.23
Net Profit 0.11
Net Profit Margin (%) 0.82
Earnings Per Share (EPS) 0.11
EBITDA 0.94
Effective Tax Rate (%) 26.66
Particulars MAR 2025 (Values in Cr)
Revenue 7.96
Operating Expense 7.94
Net Profit 0.01
Net Profit Margin (%) 0.12
Earnings Per Share (EPS) 0.01
EBITDA 0.92
Effective Tax Rate (%) 50.00
Particulars DEC 2024 (Values in Cr)
Revenue 10.77
Operating Expense 10.26
Net Profit 0.22
Net Profit Margin (%) 2.04
Earnings Per Share (EPS) 0.22
EBITDA 1.31
Effective Tax Rate (%) 57.69
Particulars MAR 2025 (Values in Cr)
Revenue 36.93
Operating Expense 36.31
Net Profit 0.30
Net Profit Margin (%) 0.81
Earnings Per Share (EPS) 0.30
EBITDA 3.78
Effective Tax Rate (%) 54.68
Particulars MAR 2024 (Values in Cr)
Revenue 43.26
Operating Expense 42.71
Net Profit 0.42
Net Profit Margin (%) 0.97
Earnings Per Share (EPS) 0.42
EBITDA 3.69
Effective Tax Rate (%) 25.00
Particulars MAR 2023 (Values in Cr)
Revenue 51.31
Operating Expense 50.19
Net Profit 0.89
Net Profit Margin (%) 1.73
Earnings Per Share (EPS) 0.96
EBITDA 4.35
Effective Tax Rate (%) 20.35
Particulars MAR 2022 (Values in Cr)
Revenue 58.96
Operating Expense 56.81
Net Profit 1.59
Net Profit Margin (%) 2.69
Earnings Per Share (EPS) 1.82
EBITDA 5.68
Effective Tax Rate (%) 28.88
Particulars MAR 2021 (Values in Cr)
Revenue 51.36
Operating Expense 50.92
Net Profit 3.28
Net Profit Margin (%) 6.38
Earnings Per Share (EPS) 3.75
EBITDA 7.08
Effective Tax Rate (%) 23.54
Particulars MAR 2025 (Values in Cr)
Book Value / Share 34.11
ROE % 1.00
ROCE % 4.94
Total Debt to Total Equity 0.54
EBITDA Margin 9.17
Particulars MAR 2024 (Values in Cr)
Book Value / Share 33.82
ROE % 1.43
ROCE % 4.75
Total Debt to Total Equity 0.53
EBITDA Margin 9.02
Particulars MAR 2023 (Values in Cr)
Book Value / Share 33.43
ROE % 3.30
ROCE % 6.04
Total Debt to Total Equity 0.56
EBITDA Margin 8.79
Particulars MAR 2022 (Values in Cr)
Book Value / Share 32.44
ROE % 5.61
ROCE % 8.36
Total Debt to Total Equity 0.58
EBITDA Margin 9.65
Particulars MAR 2025 (Values in Cr)
Book Value / Share 34.11
ROE % 0.88
ROCE % 4.49
Total Debt to Total Equity 0.47
EBITDA Margin 10.24
Particulars MAR 2024 (Values in Cr)
Book Value / Share 33.82
ROE % 1.28
ROCE % 4.24
Total Debt to Total Equity 0.47
EBITDA Margin 8.53
Particulars MAR 2023 (Values in Cr)
Book Value / Share 33.43
ROE % 2.96
ROCE % 5.67
Total Debt to Total Equity 0.53
EBITDA Margin 8.48
Particulars MAR 2022 (Values in Cr)
Book Value / Share 32.44
ROE % 5.77
ROCE % 8.80
Total Debt to Total Equity 0.53
EBITDA Margin 9.65
Particulars MAR 2021 (Values in Cr)
Book Value / Share 30.61
ROE % 1.59
ROCE % 5.01
Total Debt to Total Equity 0.45
EBITDA Margin 6.46
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 0.22
Total Assets 65.14
Total Liabilities 65.14
Total Equity 34.11
Share Outstanding 1
Price to Book Ratio 0.91
Return on Assets (%) 0.51
Return on Capital (%) 0.66
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 0.17
Total Assets 58.80
Total Liabilities 58.80
Total Equity 33.81
Share Outstanding 1
Price to Book Ratio 1.04
Return on Assets (%) 0.80
Return on Capital (%) 0.94
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 0.09
Total Assets 58.23
Total Liabilities 58.23
Total Equity 31.70
Share Outstanding 0
Price to Book Ratio 0.82
Return on Assets (%) 1.69
Return on Capital (%) 2.06
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 0.06
Total Assets 56.44
Total Liabilities 56.44
Total Equity 28.36
Share Outstanding 0
Price to Book Ratio 0.89
Return on Assets (%) 2.82
Return on Capital (%) 3.62
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 0.21
Total Assets 58.58
Total Liabilities 58.58
Total Equity 34.11
Share Outstanding 1
Price to Book Ratio 0.91
Return on Assets (%) 0.50
Return on Capital (%) 0.6
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 0.16
Total Assets 56.29
Total Liabilities 56.29
Total Equity 33.81
Share Outstanding 1
Price to Book Ratio 1.04
Return on Assets (%) 0.74
Return on Capital (%) 0.88
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 0.09
Total Assets 56.63
Total Liabilities 56.63
Total Equity 31.70
Share Outstanding 0
Price to Book Ratio 0.82
Return on Assets (%) 1.57
Return on Capital (%) 1.92
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 0.06
Total Assets 56.44
Total Liabilities 56.44
Total Equity 28.36
Share Outstanding 0
Price to Book Ratio 0.89
Return on Assets (%) 2.82
Return on Capital (%) 3.62
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 0.05
Total Assets 49.88
Total Liabilities 49.88
Total Equity 26.76
Share Outstanding 0
Price to Book Ratio 0.95
Return on Assets (%) 6.57
Return on Capital (%) 8.26
Particulars MAR 2025 (Values in Cr)
Net Income 0.69
Cash from Operations 3.92
Cash from Investing -2.31
Cash from Financing -1.42
Net change in Cash -0.02
Free Cash Flow 6.25
Particulars MAR 2024 (Values in Cr)
Net Income 0.62
Cash from Operations 1.01
Cash from Investing -1.00
Cash from Financing 0.28
Net change in Cash 0.06
Free Cash Flow 2.03
Particulars MAR 2023 (Values in Cr)
Net Income 1.24
Cash from Operations 2.04
Cash from Investing -2.26
Cash from Financing 0.62
Net change in Cash 0.02
Free Cash Flow 2.89
Particulars MAR 2022 (Values in Cr)
Net Income 2.24
Cash from Operations 1.44
Cash from Investing -2.44
Cash from Financing 1.67
Net change in Cash 0.00
Free Cash Flow 3.90
Particulars MAR 2025 (Values in Cr)
Net Income 0.64
Cash from Operations 3.35
Cash from Investing -2.31
Cash from Financing -0.86
Net change in Cash -0.02
Free Cash Flow 5.68
Particulars MAR 2024 (Values in Cr)
Net Income 0.55
Cash from Operations 2.16
Cash from Investing -1.20
Cash from Financing -0.68
Net change in Cash 0.06
Free Cash Flow 3.18
Particulars MAR 2023 (Values in Cr)
Net Income 1.12
Cash from Operations 2.59
Cash from Investing -2.26
Cash from Financing 0.05
Net change in Cash 0.03
Free Cash Flow 3.44
Particulars MAR 2022 (Values in Cr)
Net Income 2.24
Cash from Operations 1.44
Cash from Investing -2.44
Cash from Financing 1.67
Net change in Cash 0.00
Free Cash Flow 3.90
Particulars MAR 2021 (Values in Cr)
Net Income 4.29
Cash from Operations 2.08
Cash from Investing -3.66
Cash from Financing 2.07
Net change in Cash 0.02
Free Cash Flow 5.76
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
AMBALAL SARABHAI ENT L 33.07 13.67 1.60 253.43 23.12 40.00
BLISS GVS PHARMA LTD. 300.20 24.29 2.66 3175.78 118.35 304.30
CIPLA LTD 1398.95 27.70 3.28 113007.26 1165.55 1672.20
FERMENTA BIOTECH LTD. 302.65 10.07 2.27 890.73 256.40 399.00
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
AMBALAL SARABHAI ENT L 33.07 23.13 4.26 253.43 23.12 40.00
AMRUTAJAN HEALTH LTD 558.20 25.02 4.35 1613.79 490.00 789.95
ASTRAZENECA PHARMA INDIA LTD. 8604.25 103.40 26.92 21510.63 7630.00 10653.05
BLISS GVS PHARMA LTD. 300.20 32.28 2.74 3175.78 118.35 304.30

Concord Drugs Limited shareholding pattern

Holding
45.6%
54.39%
Name Shares Category
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)

News

Left Arrow
Right Arrow

Concord Drugs Limited Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
77.74 -2.82 redarrow
red-green-graph indicator
14 Bearish
2 Bullish
  • 5 Days 79.60
  • 26 Days 80.80
  • 10 Days 80.40
  • 50 Days 79.90
  • 12 Days 80.70
  • 100 Days 78.00
  • 20 Days 80.90
  • 200 Days 71.90
80.11 PIVOT
First Support 79.89 First Resistance 80.23 Second Support 79.77 Second Resistance 80.45 Third Support 79.55 Third Resistance 80.57
RSI 42.71 ADX 15.59 MACD -0.12 Williams % R -93.26 Commodity Channel Index (CCI) -141.82
Date 2026-05-22 Week 2554.00 Same Day 2286.00 Month 3257.00
1 Year 0.34 3 Year 0.61
Over 1 Month
-10.10% down
Over 1 Year
143.16% down
Over 3 Months
-3.62% down
Over 3 Years
39.23% down
Over 6 Months
3.65% down
Over 5 Years
16.97% down

Concord Drugs Limited Corporate Actions

Top Gainers

Top Losers

Concord Drugs Limited Share Price

Concord Drugs Limited, established in 1995, is amongst the respected pharmaceutical companies in India for manufacturing of Finished Pharmaceutical Formulations like Injectables (Small Volume parenterals, Dry Syrup powder) ,Tissue Bio-Adhesive, tablets, capsules and ophthalmic preparations and Ready-to-fill Pellets.

The principal activity of the Company is to manufacture licensed drugs based on the formulations approved. The Company has two manufacturing facilities license issued by The Government of Andhra Pradesh, Drugs Control Administration, and Hyderabad. State of the art technology having dedicated manufacturing facilities for Liquid Injections, Dry powder Injections and Ready-to-fill Pellets ensures the highest level of process integrity and product quality.

The Company started with Finished Pharmaceutical Formulations and then diversified into Ready-to-fill Pellets, to provide customers with end-to-end solution to their various pharmaceutical product needs to commercial contract drug manufacturing. It is engaged in developing New products Viz MUPS (Multiple Unit Pellet System), Sustained Release, Modified Release pellets with Innovative Drug Delivery Technologies by utilizing best and latest processing machinery. It operates a state of the art, cGMP contract manufacturing Formulation-Fill-Finish facility, providing comprehensive pharmaceutical development and manufacturing services for drug products.

Parent organization Indian Private
NSE symbol [-]
Founded 1995
stock
Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Concord Drugs Ltd?

Answer Field

Concord Drugs Ltd share price is for NSE ₹ 0.00 & for BSE ₹ 77.74 as on May 22 2026 03:25 PM.

What is the Market Cap of Concord Drugs Ltd Share?

Answer Field

The market cap of Concord Drugs Ltd for NSE ₹ 0.00 & for BSE ₹ 102.40 as on May 22 2026 03:25 PM.

What is the 52 Week High and Low of Concord Drugs Ltd?

Answer Field

The 52 Week High and Low of Concord Drugs Ltd for NSE is ₹ 0.00 and ₹ 0.00 and for BSE is ₹ 92.52 and ₹ 29.00.

What is 1 year return for Concord Drugs Ltd?

Answer Field

The 1 year returns on the stock has been 143.16%.

What is the P/E Ratio of Concord Drugs Ltd Share?

Answer Field

As on May 22 2026 03:25 PM the price-to-earnings (PE) ratio for Concord Drugs Ltd share is 194.35.

What is the PB ratio of Concord Drugs Ltd Share?

Answer Field

As on May 22 2026 03:25 PM, the price-to-book (PB) ratio for Concord Drugs Ltd share is 34.87.

How to Buy Concord Drugs Ltd Share?

Answer Field

You can trade in Concord Drugs Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Concord Drugs Ltd Share on Bajaj Broking App?

Answer Field

To buy Concord Drugs Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Concord Drugs Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

close-image

Get Free Demat Account*

+91
close-img

Authorise with OTP

Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59
banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|